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Abstract
Background: The Patient-Reported Outcomes Measurement Information System (PROMIS) assesses
multiple aspects of patient well-being but has not been thoroughly studied amongst orthopedic oncology
patients.
Questions/purposes: How do preoperative/early postoperative PROMIS scores compare in patients with
benign versus malignant soft tissue tumors (STTs) for (1) physical function, (2) pain interference, and (3)
depression? Are the differences clinically relevant? What other patient/tumor factors impact PROMIS?
Methods: This retrospective cohort study included 314 STT patients who underwent resection of a benign (n
= 187) or malignant (n = 127) STT over a period of 4.25 years at a single institution. PROMIS physical
function, pain interference, and depression scores were collected preoperatively and at two and six weeks
postoperatively. Scores for each time point were compared between groups and to preoperative baselines.
Backward-stepwise linear mixed-effects models were produced to identify independent predictors of change
in each PROMIS domain. The minimal clinically important difference (MCID) was 4 points.
Results: The malignant cohort, but not the benign cohort, demonstrated clinically relevant worsening of
physical function postoperatively. Malignant diagnosis (△ = −4.4, p < 0.001) and lower extremity tumors (△ =
−4.5, p < 0.001) were identified as clinically relevant, independent predictors of worse physical function at all
time points. No predictors of clinically relevant changes in pain interference or depression scores, including
malignancy, were identified.
Conclusions: In STT patients, malignancy and lower extremity STT location are associated with clinically
relevant worsening in physical function but do not significantly impact pain interference or depression in
the early postoperative period. These findings may help establish the utility of PROMIS in an orthopedic
oncology population.

Categories: Oncology, Orthopedics
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Introduction
Anticipating patient outcomes is critical for medical decision-making, preoperative counseling, and
postoperative care. Historically, outcome measures have been largely objective and physician-reported, but
recently, patient-reported outcome measures have been increasingly used in clinical practice and research
[1]. The Patient-Reported Outcomes Measurement Information System (PROMIS) is a computer-adaptive
test (CAT) developed by the National Institutes of Health to address deficiencies in traditional fixed-length
assessment systems [2]. PROMIS utilizes a series of probability-based computer algorithms to provide the
minimum number of informative questions while still achieving high measurement precision [2].
Furthermore, in addition to assessing physical function, PROMIS has domains for pain interference,
depression, anxiety, fatigue, and role functioning, which are designed to capture a broader concept of wellbeing that incorporates elements of mental and social health [1,2]. There is currently a widespread initiative
for the adoption and inclusion of PROMIS domains in Food and Drug Administration (FDA)- and industryfunded clinical oncology outcomes research [3,4].
PROMIS has been shown to be sensitive to changes in physical function, pain interference, and depression
in studies that expected effects in these domains [5-7]. It has also been found to correlate highly with
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traditional patient-reported outcomes measurement systems, with the added benefits of reduced floor and
ceiling effects, increased reliability, and greatly reduced test length [8-11]. PROMIS has performed well in a
variety of orthopedic specialties, including hand, shoulder, foot and ankle, sports, and trauma [9,12-14]. For
example, Chen et al. demonstrated that PROMIS scores significantly improved in patients undergoing ACL
reconstruction and have the ability to predict postoperative outcomes [13]. However, the ability of PROMIS
to detect differences in patient-reported outcomes in the setting of adult sarcoma has only recently been
examined in a small number of studies [15-16]. Additionally, no studies have been performed comparing
pre- and postsurgical PROMIS scores in patients with benign versus malignant soft tissue tumors (STTs).
Such information would provide context for PROMIS scores gathered for these groups in the perioperative
period.
The purpose of this study was to examine perioperative changes and outcomes for patients undergoing
resection of benign versus malignant STTs. The first hypothesis was that PROMIS physical function, pain
interference, and depression domain scores would be significantly different between patients with malignant
versus benign STTs. The second hypothesis was that PROMIS would be able to detect changes in these
domains over the perioperative period and that the magnitude of change would be clinically relevant. The
third hypothesis was that patient- and tumor-specific factors (e.g., age, sex, STT location, and STT diameter)
would impact these PROMIS domains. The goal of this project was to provide information to help providers,
researchers, and patients interpret PROMIS scores in the setting of STTs as well as add to the limited body of
literature validating PROMIS scores in this population [15,17].

Materials And Methods
This retrospective cohort study included patients over 18 years of age who underwent resection of an STT by
the Orthopedic Oncology Division at Washington University School of Medicine in St. Louis and was
approved by IRB ID 201604100 named "PROMIS and Orthopaedic Oncology." An a priori power analysis was
performed to calculate the appropriate number of study participants. Considering the minimal clinically
important difference (MCID) published for these PROMIS assessments in oncology patients and in a recent
study of patients undergoing surgery for lower extremity metastases, we designed our study to detect a
difference of 4 points on each PROMIS CAT between groups [18]. Expecting a 10-point standard deviation
on these scales and setting the alpha at 0.05 with a power of 0.80, we calculated that a total of 196 patients
would be required to demonstrate a statistically significant difference between the two groups. Patients
were included over a 4.25-year period from July 2015 until October 2019.
Medical records were reviewed for patient age and gender, histologic diagnosis, tumor size, and tumor
location (axial/pelvic vs. appendicular, upper vs. lower extremity). Computer-adaptive PROMIS surveys were
administered on tablet computers (Apple, Cupertino, CA). Patients were asked to complete the PROMIS
physical function, pain interference, and depression domains at their preoperative, two-week postoperative,
and six-week postoperative clinic appointments. All PROMIS measures were scored with a theoretical range
of 0-100 and were scaled to have the normal United States population average of 50 (SD ± 10 points). Higher
scores always indicate more of the domain being tested; thus, a score of 60 for physical function indicates a
better than average functionality, while a score of 60 on pain interference indicates a greater impact of pain
on life. Patients were aware of their diagnoses (i.e., benign versus malignant STT) at the time of their
preoperative visit. Patients with benign tumors that had made full recovery (defined as complete wound
healing, resolution of symptoms, return to full activity, and discontinuation of pain medication) by two
weeks postoperative were only asked to return for a six-week follow-up if they experienced any change in
their status. In these situations (n = 132), the two-week scores were also used as six-week scores if the
patient did not return.
A total of 394 patients underwent STT resection during the enrollment period. Of these, 46 patients were
excluded for surgical treatment that required bone resection or amputation, and 16 were excluded for not
having completed the PROMIS surveys during their office visits. An additional 18 patients were excluded due
to a lack of follow-up. Of the remaining 314 patients, 187 had benign and 127 had malignant STTs, as
diagnosed by histopathologic analysis.

Statistical analysis
A Pearson’s chi-squared test was performed to compare the benign and malignant STT groups for the
categorical variables of sex, axial/pelvic versus appendicular location, upper extremity versus lower
extremity location, and tumor size greater than 5 cm versus less than 5 cm. ANOVA and two-tailed, unpaired
t-tests were used to compare preoperative versus postoperative PROMIS scores within each cohort and to
make univariate comparisons between the cohorts. Pearson’s correlation was performed to assess whether
changes in the scores of one PROMIS domain were associated with changes in other PROMIS domains.
Backward-stepwise, repeated measures mixed models were used to detect the independent effects of
demographic variables and time since surgery on each PROMIS domain. All seven collected variables were
eligible for inclusion in the model, and variables with a p-value greater than 0.1 were excluded by the
stepwise procedure. In all statistical analyses, p-values less than 0.05 were considered significant.

Results
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Table 1 presents comparisons of demographic and tumor information between the malignant and benign
STT cohorts. Physical function was significantly worse in patients with malignant tumors compared to those
with benign tumors at all time points (p < 0.05; Figure 1 and Table 2). The malignant cohort had a
significantly worse physical function at two weeks (p < 0.001) and six weeks (p = 0.005) postoperatively
compared to their preoperative baselines. The average change in physical function for malignant patients at
both two weeks (Δ = −6.1) and six weeks (Δ = −4.4) postoperatively was greater than the MCID of 4 points
established for this study (Table 3). Additionally, while physical function scores improved between two and
six weeks after surgery for patients with benign STTs, we observed no significant improvement in the
malignant STT cohort (p =0.28). Independent predictors of worsened physical function are listed in Table 2.
Of these, only malignant STT diagnosis (Δ = −4.4, p < 0.001) and upper extremity tumor location (Δ = 4.5, p <
0.001) exceeded MCID cutoff values.

Factor

Total (N=314)

Benign STT (N=186)

Malignant STT (N=128)

p-value

Age

54.7±18.7

50.7±18.0

60.5±18.1

<0.001a

Female

161 (51%)

112 (60%)

49 (38%)

Male

153 (49%)

74 (40%)

79 (62%)

Lower extremity

225 (72%)

130 (70%)

95 (74%)

Upper extremity

89 (28%)

56 (30%)

33 (26%)

Appendicular skeleton

280 (89%)

176 (95%)

104 (81%)

Axial skeleton

34 (11%)

10 (5%)

24 (19%)

Tumor diameter (cm)

8.3±6.0

7.7±5.4

9.1±6.6

Tumor diameter >5 cm

130 (41%)

87 (47%)

43 (34%)

Tumor diameter <5 cm

184 (59%)

99 (53%)

85 (66%)

Sex

<0.001b

0.40b

Tumor location

Tumor size

<0.001b

0.050a

0.020b

TABLE 1: Comparisons of benign vs. malignant cohort demographic information
Values are presented as mean ± SD or N (column %).
p-values: aANOVA, bPearson's chi-square test.

FIGURE 1: Graphical representation of PROMIS scores for physical
function
Significant p-values indicated in red
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Physical function
Independent predictors

Effect size (change in physical function score)

95% confidence interval

p-value

Time since surgery

−1.93

−2.5 to −1.3

<0.001

Age (years)

−0.1

−0.03 to −0.2

<0.001

Male sex

2.4

0.3–4.4

0.03

Malignant tumor

−4.4

−6.6 to −2.3

<0.001

Upper extremity

4.5

2.3–6.8

<0.001

Independent predictors

Effect size (change in pain interference score)

95% confidence interval

p-value

Time since surgery

1.2

0.6–1.8

<0.001

Upper extremity

−3.2

−5.4 to −1.0

0.003

Tumor diameter (cm)

0.2

0.04 to 0.4

0.02

Independent predictors

Effect size (change in depression score)

95% confidence interval

p-value

Time since surgery

−0.6

−1.1 to −0.2

<0.001

Upper extremity STT

−2.8

−5.1 to −0.5

0.001

Pain interference

Depression

TABLE 2: Results of backward-stepwise, repeated-measures mixed models
STT: soft tissue tumor

Physical function

Pain interference

Standard
Perioperative time

Benign

Standard
Malignant

error

Depression

Standard
Benign

error

Standard
Malignant

error

Standard
Benign

error

Standard
Malignant

error

error

Preoperative

47.0

0.79

43.0

0.93

55.1

0.79

54.8

0.93

46.2

0.72

46.8

0.9

2 week postoperative

45.1

2.43

36.9

1.08

58.2

0.74

60.2

0.88

44.9

0.84

46.8

0.9

6 week postoperative

45.8

2.44

38.6

1.20

56.9

0.77

58.1

0.97

44.4

0.85

46.8

1.09

Change from preoperative vs. 2 weeks
−1.9

−6.1

3.2

5.3

−1.2

−4.4

1.8

3.2

−1.3

0.0

postoperative

Change from preoperative vs. 6 weeks
postoperative

TABLE 3: Mean PROMIS results for physical function, pain interference, and depression domains
for benign and malignant STT cohorts across perioperative time points
The numbers indicated in bold are those that reached that minimal clinically important difference of 4.

Interference scores did not differ significantly between patients with benign tumors compared to patients
with malignant tumors at any time point (Figure 2 and Table 2). In patients with benign tumors, pain
interference was significantly increased two weeks postoperatively compared to the preoperative baseline (p
= 0.003). Pain interference scores recovered to preoperative levels by six weeks in the benign STT cohort (p =
0.08). In patients with malignant tumors, both two- and six-week postoperative pain interference scores
were significantly higher (indicating worse pain) than the preoperative baseline (p < 0.05). Time since surgery
(Δ = 1.2 at 2 weeks, Δ = 2.4 at 6 weeks, p < 0.001), upper extremity tumor location (Δ = −3.2, p = 0.003), and
tumor diameter (Δ = 0.2/cm, p = 0.02) were identified as independent predictors of change in pain
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interference scores (Table 2). However, none of these factors exceeded the MCID cutoff.

FIGURE 2: Graphical representation of pain interference PROMIS scores

Depression scores remained similar between benign and malignant diagnoses across all time points (p >
0.05; Figure 3). Neither the benign nor malignant cohorts exhibited significant variation in PROMIS
depression scores over time (p > 0.05). Considering all patients, PROMIS depression scores improved by a
mean of 3.77 points postoperatively (p = 0.032). Upper extremity STT location (Δ = 2.8, p = 0.001) and
increased time since surgery (Δ = 0.6 at 2 weeks, Δ = 1.2 at 6 weeks, p < 0.001) independently predicted
improved depression scores (Table 2). However, none of these factors exceeded the MCID cutoff.

FIGURE 3: Graphical representation of depression PROMIS scores

Increased depression was associated with increasing pain interference preoperatively (r = 0.53, p < 0.001),
two weeks postoperatively (r = 0.60, p < 0.001), and six weeks postoperatively (r = 0.63, p < 0.001). Increased
depression was also associated with decreased physical function preoperatively (r = −0.41, p < 0.001), two
weeks postoperatively (r = −0.34, p = 0.001), and six weeks postoperatively (r = −0.045, p < 0.001). Similarly,
increased pain interference was associated with decreased physical function preoperatively (r = −0.64, p <
0.001), two weeks postoperatively (r = −0.63, p < 0.001), and six weeks postoperatively (r = −0.69, p < 0.001).

Discussion
The malignant STT cohort differed from the benign STT cohort in terms of increased age, male
predominance, increased percentage of tumors affecting the axial skeleton, increased overall tumor
diameter, and increased percentage of tumors greater than 5 cm. Of these factors, only age and male sex
were noted to be independent predictors of change in any of the measured PROMIS domains. Neither of
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these factors met the MCID cutoff. Despite the differences in age between our cohorts, our malignant STT
group reflects the age distribution of patients with STTs in a recent, large epidemiologic study, so our
findings are likely generalizable to this population [19]. Finally, tumor diameter was found to be an
independent predictor of pain interference, but this also did not meet the MCID cutoff.
In this study, PROMIS was able to detect significant differences in physical function in patients with
malignant tumors compared to those with benign tumors at all time points. Additionally, compared to their
preoperative scores, patients with malignant STTs experienced decreases in physical function that exceeded
MCID cutoffs at both two and six weeks postoperatively, whereas physical function changes in patients with
benign STTs did not exceed the MCID cutoff at either time point. While pain interference scores in patients
with benign tumors recovered by six weeks postoperatively, patients with malignant tumors did not exhibit
similar recovery. Variations in each of the three PROMIS domains studied were associated with changes in
the other two domains at each of the perioperative time points measured, consistent with the existing
orthopedic literature [20-22].

Physical function domain
Several studies have shown that PROMIS effectively measures changes in physical function during the 6week postoperative period [23,24]. In our population, PROMIS detected differences in physical function
experienced by patients with malignant STTs both postoperatively compared to their preoperative baselines
and compared to patients with benign STTs. Factors identified as independent predictors of decreased
physical function included malignant diagnosis and older age. Of these variables, only malignant STT
diagnosis exceeded MCID cutoffs. The more aggressive operations that are required to achieve negative
margins and the adverse physiologic effects of chemotherapy and radiation may have contributed to
worsening the physical function associated with a malignant diagnosis [25]. Additionally, quality of life
research has indicated that a diagnosis of malignancy takes a significant emotional, social, and physical toll
[26]. Notably, prior work has emphasized that the rareness of STS has hindered research into the specific
impact that STS have on patient well-being, which highlights the importance of preliminary work such as
this [27]. These data may help patients, families, and employers understand that physical function recovery
may be prolonged and incomplete.

Pain interference domain
Preoperative pain interference scores were not significantly different in the benign compared to malignant
STT cohorts (p = 0.77). This is consistent with the principle that sarcomas most often present as painless
masses. While pain interference scores were elevated two weeks postoperatively in all STT patients, they
returned to their preoperative baseline by six weeks in the benign cohort but not in the malignant cohort.
The increase in pain interference at two weeks postoperatively exceeded MCID cutoffs for the malignant
cohort only. This suggests that the more aggressive, complex surgeries needed to excise malignant tumors
may cause more pain in the postoperative period, even without increased pain in the preoperative period.
Additionally, because no benign STTs received pre- or postoperative radiation, it was not possible to control
for the effect of this variable in our analysis comparing benign versus malignant STTs. Presumably, the
effect of radiation would impact pain and likely play a role in driving the difference noted in PROMIS pain
interference scores. Increasing time since surgery was found to increase pain interference, albeit by a nonclinically significant amount. This is likely a result of our relatively short postoperative follow-up. These
results may have implications for setting patient expectations and managing postoperative analgesia.

Depression domain
PROMIS depression scores were similar in patients with benign and malignant STTs across all time points.
The multivariate analysis demonstrated significantly lower depression scores (improved depressive
symptoms) in patients with upper extremity tumors compared to lower extremity tumors. It is possible that
patients with lower extremity STTs experienced more severe depression due to their clinically significant
increase in functional impairment postoperatively (e.g., difficulty ambulating). Development or
exacerbation of depression in the setting of postoperative lower extremity weakness is consistent with
current literature linking worse performance on tests of lower extremity physical function (e.g., the 8-foot
up and go test, the 30-second chair stand test) to worsening of depressive symptoms [28]. Time since surgery
was also found to independently predict lower depression scores, which would be expected following
resection of a tumor.

Limitations
This study has several limitations. Because most benign STTs do not require longer follow up, it includes
only the early postoperative period. Thus, our results do not capture intermediate or long-term effects on
PROMIS scores. Future goals for this project would be to obtain longer term follow-up with this patient
population, which could enable detection of latent effects beyond the perioperative period. Second, our
benign and malignant STT groups differed significantly in terms of age, sex, tumor diameter, and tumor
location (axial versus appendicular). Multivariable analyses did not demonstrate that patient sex, tumor
diameter, or axial versus appendicular location significantly affected PROMIS outcomes. We found increased
age to be predictive of poorer outcomes on physical function scores, so this could be a confounding factor for
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the univariate analyses presented. However, age did not meet the MCID cutoff established for this project.
Additionally, the data for this project did not include an assessment of tumor depth, which may have an
impact on PROs. However, prior large, multivariate analyses have noted that the potential prognostic value
of STT depth can be explained by deeper-seated tumors tending to have a larger mean size, which is
captured by this project [29,30].

Conclusions
PROMIS can detect changes in physical function, pain interference, and depression during early follow-up
after STT excision. Patients with malignant STTs are at a greater risk for increased functional deficits and
may have greater pain postoperatively. While PROMIS depression scores were higher in patients with lower
extremities than in upper extremity STTs, depression scores improved in both groups following the removal
of the tumor. Additional research on these and other PROMIS domains is needed to explore the clinical
relevance of our findings, determine the long-term outcomes of surgery, and further define the utility of
PROMIS in the orthopedic oncology population.
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